Abstracts presented at ASCO GU examined whether the radioligand therapy impacts or is affected by ARPIs or chemotherapy.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.

Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...

However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

A drug for advanced prostate cancer has shown "remarkable" results in an early-stage trial, experts have said.

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...